Terumo, CSL Plasma Mutually Terminate Supply Agreement; Terumo Expects $610 Million Loss
MT Newswires Live
Yesterday
Terumo (TYO:4543) has mutually agreed with CSL Plasma to end their supply agreement for source plasma collection devices, and expects a loss of $610 million, according to a Thursday Tokyo bourse filing.
The loss comprises $450 million in non-cash impairment losses and $160 million in transition, termination, and restructuring costs.
Subsequently, Terumo revised its full-year guidance for the fiscal year ending March 31, 2027, cutting profit attributable to owners of the parent to 120 billion yen from 193.1 billion yen initially.
Basic earnings per share estimates dropped to 81.35 yen from 130.91 yen, while revenue targets were cut to 1.23 trillion yen from 1.239 trillion yen.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.